ABBV

AbbVie Inc.

NYSE · Biopharmaceuticals · Health Care · 2025-12-31

AbbVie reports prescription medicines across immunology, neuroscience, oncology and other portfolios. The earnings release separates GAAP earnings from adjusted results and separately identifies acquired research and development charges.

Reported financial & operating measures

Historical disclosures · USD amounts in millions unless stated otherwise · Fiscal periods differ by issuer

Selected annual company metrics with period, units and accounting basis
Measure	Value	Unit	Period	Basis / precision
Net revenues	61,160	USD million	FY2025	GAAP
Operating earnings	15,075	USD million	FY2025	GAAP
Net earnings attributable to AbbVie	4,226	USD million	FY2025	GAAP
Research and development	9,096	USD million	FY2025	GAAP
Acquired IPR&D and milestones	5,016	USD million	FY2025	GAAP
Immunology portfolio net revenues	30,406	USD million	FY2025	GAAP
Skyrizi net revenues	17,562	USD million	FY2025	GAAP
Rinvoq net revenues	8,304	USD million	FY2025	GAAP
Humira net revenues	4,540	USD million	FY2025	GAAP
Diluted EPS	2.36	USD/share	FY2025	GAAP
Net revenues	56,334	USD million	FY2024	GAAP
Net earnings attributable to AbbVie	4,278	USD million	FY2024	GAAP

Source reviewed: 2026-11-15. Selected measures, not a full set of audited statements or live stock prices.

Sources

https://news.abbvie.com/2026-02-04-AbbVie-Reports-Full-Year-and-Fourth-Quarter-2025-Financial-Results